TScan Therapeutics Inc Virtual KOL Event Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gaurav Maini - LifeSci Capital LLC - Analyst : Hi, congrats on the data update. This is Gaurav Maini for Sam Slutsky from LifeSci Capital. Just a couple of questions from us. So firstly, as it relates to TSC-101 retreatment, are you allowed to retreat in the Phase 3 protocol? And if so, maybe any color on how those patients would be counted towards RFS. And then just a follow-up if you don't mind.

Question: Gaurav Maini - LifeSci Capital LLC - Analyst : Yeah, makes sense. Thank you. And just one more if you don't mind. So the control arm on both TP53 status and pre-HCT MRD status, maybe can you discuss the historical impact of those baselines on patient outcomes what this means as it relates to the magnitude of difference we are seeing in the ALLOHA trial, and then what you plan to do in Phase 3 to perhaps better ensure that baselines between the treatment and control are aligned.

Question: Selena Zhang - Morgan Stanley - Analyst : Hi, this is Selena on for Max. Thank you for taking our question. On the commercial-ready process, did the two patients have product manufactured at dose level 4? And if the patients were dosed, are there any observations you can share thus far? Thank you.

Question: David Nierengarten - Wedbush Securities Inc - Analyst : Thanks. I just, maybe this is an obvious question, but why not just use the manufacturing process that you're used to and maybe split the dose, or go to or stay with dose level 3 in the Phase 3 study. Thanks.